| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| 25g |
|
||
| Other Sizes |
| Targets |
The compound itself does not have a specific pharmacological target as it is a synthetic intermediate (protected amino acid) rather than a therapeutic agent. Its value lies in its use as a building block for the synthesis of peptides and peptide-based pharmaceuticals. The carbobenzoxy (Cbz) protecting group is used to protect the amino group during peptide synthesis, preventing unwanted side reactions.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
Carbobenzoxyphenylalanine itself is not known to possess direct therapeutic activity. Its significance is as a synthetic intermediate for the preparation of peptides and peptide-based pharmaceuticals. The compound is used in peptide synthesis to introduce the phenylalanine residue into peptide sequences while protecting the amino group with the Cbz group, which can be removed by hydrogenation or other methods after peptide assembly. |
| ln Vivo |
There is no reported in vivo activity for carbobenzoxyphenylalanine itself, as it is primarily a chemical intermediate rather than a drug candidate. Its role in drug discovery is indirect, serving as a building block for the synthesis of peptides that are then evaluated for biological activity.
|
| Enzyme Assay |
As a chemical intermediate, there are no standardized in vitro enzyme/receptor binding assays for carbobenzoxyphenylalanine itself. The compound's utility is in peptide synthesis rather than biological assay development. Researchers may use carbobenzoxyphenylalanine as a starting material to synthesize peptides that are then evaluated in various biological assays.
|
| Cell Assay |
There are no reported in vitro cellular assays for carbobenzoxyphenylalanine itself, as it is not a drug candidate. The compound is used in peptide synthesis to prepare peptides that may subsequently be tested in cellular assays for various biological activities.
|
| Animal Protocol |
There are no reported in vivo animal studies for carbobenzoxyphenylalanine itself, as the compound is a synthetic intermediate rather than a therapeutic agent. Animal studies would be conducted on the final peptide products synthesized from carbobenzoxyphenylalanine rather than on the intermediate itself.
|
| ADME/Pharmacokinetics |
As a synthetic intermediate, there are no reported pharmacokinetic data for carbobenzoxyphenylalanine. Pharmacokinetic studies would be performed on the final peptide molecules synthesized from carbobenzoxyphenylalanine rather than on the intermediate itself.
|
| Toxicity/Toxicokinetics |
As a synthetic intermediate used in peptide synthesis, carbobenzoxyphenylalanine is not intended for human consumption, and there are no reported toxicity data for the compound itself. Toxicology studies would be conducted on the final peptide products synthesized from carbobenzoxyphenylalanine. Appropriate safety precautions should be followed when handling the compound in the laboratory.
|
| References |
[1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-883.
|
| Additional Infomation |
Carbobenzoxyphenylalanine (Z-Phe-OH) is a protected amino acid derivative used as a building block in peptide synthesis. The compound contains a carbobenzoxy (Cbz) protecting group attached to L-phenylalanine and is widely used in solid-phase and solution-phase peptide synthesis. The Cbz group can be removed by hydrogenation, allowing for the selective deprotection of the amino group during peptide assembly. Carbobenzoxyphenylalanine is a valuable tool in medicinal chemistry for the preparation of peptide-based pharmaceuticals and research compounds.
|
| Molecular Formula |
C17H17NO4
|
|---|---|
| Molecular Weight |
299.32
|
| Exact Mass |
299.115
|
| CAS # |
1161-13-3
|
| PubChem CID |
70878
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
511.5±50.0 °C at 760 mmHg
|
| Melting Point |
85-87 °C(lit.)
|
| Flash Point |
263.1±30.1 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.591
|
| LogP |
3.58
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
22
|
| Complexity |
360
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O(C([H])([H])C1C([H])=C([H])C([H])=C([H])C=1[H])C(N([H])[C@]([H])(C(=O)O[H])C([H])([H])C1C([H])=C([H])C([H])=C([H])C=1[H])=O
|
| InChi Key |
RRONHWAVOYADJL-HNNXBMFYSA-N
|
| InChi Code |
InChI=1S/C17H17NO4/c19-16(20)15(11-13-7-3-1-4-8-13)18-17(21)22-12-14-9-5-2-6-10-14/h1-10,15H,11-12H2,(H,18,21)(H,19,20)/t15-/m0/s1
|
| Chemical Name |
(2S)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoic acid
|
| Synonyms |
NSC 402059; Carbobenzoxy-L-phenylalanine; Carbobenzoxyphenylalanine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3409 mL | 16.7045 mL | 33.4091 mL | |
| 5 mM | 0.6682 mL | 3.3409 mL | 6.6818 mL | |
| 10 mM | 0.3341 mL | 1.6705 mL | 3.3409 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
